Key Points:
- The guideline discusses the use of conventional fecal microbiota transplant (FMT) and newer FDA-approved therapies (fecal microbiota live-jslm and fecal microbiota spores live-brpk) for conditions such as recurrent Clostridioides difficile infection, severe C. difficile infections, inflammatory bowel diseases (IBD), and irritable bowel syndrome (IBS).
- FMT is suggested for immunocompetent adults after standard antibiotic treatments to prevent recurrence. It’s also recommended for mildly or moderately immunocompromised adults but is advised against in severely immunocompromised individuals.
- Severe C. difficile Infection: In cases not responding to standard antibiotics, FMT is suggested for hospitalized adults.
- The use of FMT is generally not recommended except within the context of clinical trials.